FLT3 and acute myeloid leukemia: The combination of VEN plus gilteritinib in FLT3mut patients was shown to induce a CR rate of 75% and median OS of 10 months in relapsed or refractory AML patients who had received prior FLT3 inhibitor therapy in 64% [143].